Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.58 |
| ▸ | LPL | P06858 | 4/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865195 | 0.88 | HDAC3 (0.62) | FFAR1TRPV1LPLLIPGCA1 | |
| SCHEMBL3865509 | 0.86 | MAPT (0.61) | TRPV1LPLLIPGCA1CA2 | |
| SCHEMBL69746 | 0.84 | FFAR1 (0.81) | FFAR1KEAP1CA1CA2FFAR4 | |
| SCHEMBL9945962 | 0.84 | FFAR1 (0.57) | FFAR1KEAP1CA1CA2FFAR4 | |
| Hydrochloric Acid SCHEMBL25264643 | 0.82 | FFAR1 (0.77) | FFAR1KEAP1CA1CA2FFAR4 | |
| SCHEMBL28737797 | 0.82 | LPL (0.53) | TRPV1LPLLIPGCA1CA2 | |
| SCHEMBL4382949 | 0.81 | FFAR1 (0.54) | FFAR1TRPV1CA1CA2FFAR4 | |
| SCHEMBL890400 | 0.79 | LPL (0.73) | TRPV1LPLLIPGCA1CA2 | |
| SCHEMBL207657 | 0.78 | CA2 (0.58) | FFAR1TRPV1LPLLIPGCA2 | |
| SCHEMBL3533619 | 0.78 | FFAR1 (0.87) | FFAR1KEAP1CA1CA2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720728-A1 | COATED SILICONE HYDROGEL CONTACT LENSES AND METHOD FOR MAKING THE SAME | Alcon Inc. (CH) | 2026-04-08 | — | — | EP | claimed |
| CN-116813381-B | Biological ceramic surface bioactive coating and preparation method thereof | 化学与精细化工广东省实验室潮州分中心 | 2024-12-03 | — | — | CN | claimed |
| US-20240393501-A1 | COATED SILICONE HYDROGEL CONTACT LENSES AND METHOD FOR MAKING THE SAME | ALCON INC (CH) | 2024-11-28 | — | — | US | claimed |
| WO-2024241239-A1 | COATED SILICONE HYDROGEL CONTACT LENSES AND METHOD FOR MAKING THE SAME | ALCON INC. (CH) | 2024-11-28 | — | — | WO | claimed |
| US-11931454-B2 | Wet-packed soft hydrogel ocular inserts | ALCON INC. (CH) | 2024-03-19 | — | — | US | claimed |
| CN-116813381-A | Biological ceramic surface bioactive coating and preparation method thereof | 化学与精细化工广东省实验室潮州分中心 | 2023-09-29 | — | — | CN | claimed |
| CN-114727954-A | Wet packed soft hydrogel ocular inserts | 爱尔康公司 | 2022-07-08 | — | — | CN | claimed |
| EP-4017478-A1 | WET-PACKED SOFT HYDROGEL OCULAR INSERTS | Alcon Inc. (CH) | 2022-06-29 | — | — | EP | claimed |
| EP-3746820-B1 | CONTACT LENSES WITH A LUBRICIOUS COATING THEREON | ALCON INC (CH) | 2022-02-16 | — | — | EP | claimed |
| CN-111146496-B | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2021-07-13 | — | — | CN | claimed |
| US-10962803-B2 | Contact lenses with a lubricious coating thereon | ALCON INC. (CH) | 2021-03-30 | — | — | US | claimed |
| WO-2021053586-A1 | WET-PACKED SOFT HYDROGEL OCULAR INSERTS | ALCON INC. (CH) | 2021-03-25 | — | — | WO | claimed |
| US-20210077385-A1 | WET-PACKED SOFT HYDROGEL OCULAR INSERTS | ALCON INC. (CH) | 2021-03-18 | — | — | US | claimed |
| EP-3746820-A1 | CONTACT LENSES WITH A LUBRICIOUS COATING THEREON | Alcon Inc. (CH) | 2020-12-09 | — | — | EP | claimed |
| CN-111566517-A | Contact lenses having lubricious coating thereon | 爱尔康公司 | 2020-08-21 | — | — | CN | claimed |
| CN-111146496-A | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-20190235277-A1 | CONTACT LENSES WITH A LUBRICIOUS COATING THEREON | ALCON INC. (CH) | 2019-08-01 | — | — | US | claimed |
| US-20030119178-A1 | DNA chip and its preparation | SATO KOZO (JP) | 2003-06-26 | — | — | US | claimed |
| US-20010011129-A1 | DNA chip and its preparation | FUJI PHOTO FILM CO., LTD.; | 2001-08-02 | — | — | US | claimed |
| US-20260115156-A1 | INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT | UNIV KOREA RES & BUS FOUND (KR) | 2026-04-30 | — | — | US | disclosed |
| US-12612421-B2 | Method for producing 4-borono-L-phenylalanine and intermediate thereof | STELLA PHARMA CORPORATION (JP) | 2026-04-28 | — | — | US | disclosed |
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720728-A1 | COATED SILICONE HYDROGEL CONTACT LENSES AND METHOD FOR MAKING THE SAME | Alcon Inc. (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-12545641-B2 | Amphoteric fluorescent substance capable of being attached to biomaterials | C-BIOMEX CO., LTD. (KR) | 2026-02-10 | — | — | US | disclosed |
| US-20260027239-A1 | cRGD -CONJUGATED IMAGING AGENT | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12522571-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250325713-A1 | DISEASE-TARGETED IMAGING AGENTS | CURADEL SURGICAL INNOVATIONS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4626487-A2 | CRGD -CONJUGATED IMAGING AGENT | Curadel Surgical Innovations, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250255991-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | ON TARGET LABORATORIES INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-4360659-B1 | FLUORESCENT WATER-SOLUBLE POLYCATIONIC CHITOSAN POLYMERS AS MARKERS FOR BIOLOGICAL 3D IMAGING | CYANAGEN S R L (IT) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025080691-A1 | FLUORESCENT DYES AND COMPOSITIONS COMPRISING DENDRIMERS FOR DETECTING THE PRESENCE AN ANALYTE IN A SAMPLE | BioLegend, Inc. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025059097-A1 | DISEASE-TARGETED IMAGING AGENTS | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119499396-A | Antibacterial aztreonam main ring-aggregation-induced emission molecule-siderophore conjugate and preparation method thereof | 武汉大学深圳研究院 | 2025-02-25 | — | — | CN | disclosed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| EP-4483905-A1 | RADIOLABELED FAP-ALPHA-AFFINITY COMPOUND AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2025-01-01 | — | — | EP | disclosed |
| CN-116813381-B | Biological ceramic surface bioactive coating and preparation method thereof | 化学与精细化工广东省实验室潮州分中心 | 2024-12-03 | — | — | CN | disclosed |
| US-20240393501-A1 | COATED SILICONE HYDROGEL CONTACT LENSES AND METHOD FOR MAKING THE SAME | ALCON INC (CH) | 2024-11-28 | — | — | US | disclosed |
| WO-2024241239-A1 | COATED SILICONE HYDROGEL CONTACT LENSES AND METHOD FOR MAKING THE SAME | ALCON INC. (CH) | 2024-11-28 | — | — | WO | disclosed |
| US-12144874-B2 | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer | On Target Laboratories, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118878632-A | Preparation method and application of near infrared fluorescent probe for tumor targeted imaging | 浙江义氪生物科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| WO-2024145492-A9 | cRGD -CONJUGATED IMAGING AGENT | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4105295-B1 | AMPHOTERIC FLUORESCENT SUBSTANCE CAPABLE OF BEING ATTACHED TO BIOMATERIALS | C BIOMEX CO LTD (KR) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024145492-A2 | cRGD -CONJUGATED IMAGING AGENT | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024145492-A2 | cRGD -CONJUGATED IMAGING AGENT | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240175874-A1 | FLUORESCENT WATER-SOLUBLE POLYCATIONIC CHITOSAN POLYMERS AS MARKERS FOR BIOLOGICAL 3D IMAGING | CYANAGEN S.R.L. (IT) | 2024-05-30 | — | — | US | disclosed |
| EP-4360659-A1 | FLUORESCENT WATER-SOLUBLE POLYCATIONIC CHITOSAN POLYMERS AS MARKERS FOR BIOLOGICAL 3D IMAGING | Cyanagen S.r.l. (IT) | 2024-05-01 | — | — | EP | disclosed |
| US-11945786-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11931454-B2 | Wet-packed soft hydrogel ocular inserts | ALCON INC. (CH) | 2024-03-19 | — | — | US | disclosed |
| CN-117384150-A | Thiazolidinones immunoproteasome inhibitor and its preparation method and pharmaceutical use | 中国医学科学院药物研究所 | 2024-01-12 | — | — | CN | disclosed |
| US-20230416280-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | STELLA PHARMA CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023235502-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CYCLOHEX-2-ENYLIDENE / 3,3-DIMETHYLINDOLINE COMPOUNDS; METHODS OF TREATING HUMAN DISEASES; AND METHODS OF INDUCING A CALCIUM SENSITIZING EFFECT IN A SUBJECT | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-116813381-A | Biological ceramic surface bioactive coating and preparation method thereof | 化学与精细化工广东省实验室潮州分中心 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023162946-A1 | RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2023-08-31 | — | — | WO | disclosed |
| EP-4168492-A1 | NEAR-INFRARED CYANINE DYES AND CONJUGATES THEREOF | Bracco Imaging SPA (IT) | 2023-04-26 | — | — | EP | disclosed |
| US-20230098702-A1 | AMPHOTERIC FLUORESCENT SUBSTANCE CAPABLE OF BEING ATTACHED TO BIOMATERIALS | C-BIOMEX CO., LTD. (KR) | 2023-03-30 | — | — | US | disclosed |
| EP-4147724-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | Beth Israel Deaconess Medical Center (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4105295-A1 | AMPHOTERIC FLUORESCENT SUBSTANCE CAPABLE OF BEING ATTACHED TO BIOMATERIALS | C-Biomex Co., Ltd. (KR) | 2022-12-21 | — | — | EP | disclosed |
| US-20220387631-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-20220387631-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-20220381789-A1 | NANOCOMPOSITE PARTICLES COMPRISING A BORONIC ACID MOIETY AND METHODS FOR PRODUCING AND USING THE SAME | ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA, A BODY CORPORATE (US) | 2022-12-01 | — | — | US | disclosed |
| US-20220381789-A1 | NANOCOMPOSITE PARTICLES COMPRISING A BORONIC ACID MOIETY AND METHODS FOR PRODUCING AND USING THE SAME | ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA, A BODY CORPORATE (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2022231604-A1 | NANOCOMPOSITE PARTICLES COMPRISING A BORONIC ACID MOIETY AND METHODS FOR PRODUCING AND USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3062825-B1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2022-08-24 | — | — | EP | disclosed |
| CN-114727954-A | Wet packed soft hydrogel ocular inserts | 爱尔康公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4017478-A1 | WET-PACKED SOFT HYDROGEL OCULAR INSERTS | Alcon Inc. (CH) | 2022-06-29 | — | — | EP | disclosed |
| US-20220047540-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2022-02-17 | — | — | US | disclosed |
| EP-3746820-B1 | CONTACT LENSES WITH A LUBRICIOUS COATING THEREON | ALCON INC (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| EP-3889141-A1 | (R)-3-(4'-(2-(2-METHYLPYRROLIDIN-1-YL)ETHYL)BIPHENYL-4-YL)PROPANOIC ACID AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021162133-A1 | AMPHOTERIC FLUORESCENT SUBSTANCE CAPABLE OF BEING ATTACHED TO BIOMATERIALS | (주)씨바이오멕스 | 2021-08-19 | — | — | WO | disclosed |
| US-11077210-B2 | Near-infrared fluorescent contrast bioimaging agents and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077210-B2 | Near-infrared fluorescent contrast bioimaging agents and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2021-08-03 | — | — | US | disclosed |
| CN-111146496-B | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-11061169-B2 | Contact lens with phosphorylcholine-modified polyvinylalcohols therein | ALCON INC. (CH) | 2021-07-13 | — | — | US | disclosed |
| EP-3309150-B1 | (R)-3-(4'-(2-(2-METHYLPYRROLIDIN-1-YL)ETHYL)BIPHENYL-4-YL)PROPANOIC ACID AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARM INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10962803-B2 | Contact lenses with a lubricious coating thereon | ALCON INC. (CH) | 2021-03-30 | — | — | US | disclosed |
| WO-2021053586-A1 | WET-PACKED SOFT HYDROGEL OCULAR INSERTS | ALCON INC. (CH) | 2021-03-25 | — | — | WO | disclosed |
| US-20210077385-A1 | WET-PACKED SOFT HYDROGEL OCULAR INSERTS | ALCON INC. (CH) | 2021-03-18 | — | — | US | disclosed |
| WO-2021049920-A1 | SURFACE-MODIFIED EXTRACELLULAR VESICLE AND COMPOSITION COMPRISING SAME | (주) 테라베스트 | 2021-03-18 | — | — | WO | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| EP-3746820-A1 | CONTACT LENSES WITH A LUBRICIOUS COATING THEREON | Alcon Inc. (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-20200352898-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2020-11-12 | — | — | US | disclosed |
| CN-111566517-A | Contact lenses having lubricious coating thereon | 爱尔康公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3668502-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2020100090-A1 | CONTACT LENS WITH PHOSPHORYLCHOLINE-MODIFIED POLYVINYLALCOHOLS THEREIN | ALCON INC. (CH) | 2020-05-22 | — | — | WO | disclosed |
| US-20200158913-A1 | CONTACT LENS WITH PHOSPHORYLCHOLINE-MODIFIED POLYVINYLALCOHOLS THEREIN | ALCON INC. (CH) | 2020-05-21 | — | — | US | disclosed |
| CN-111146496-A | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池有限公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-20190247357-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | ABRAXIS BIOSCIENCE, LLC | 2019-08-15 | — | — | US | disclosed |
| EP-3522854-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | Abraxis BioScience, LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | disclosed |
| EP-3519399-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | Sigilon Therapeutics, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190235277-A1 | CONTACT LENSES WITH A LUBRICIOUS COATING THEREON | ALCON INC. (CH) | 2019-08-01 | — | — | US | disclosed |
| CN-110036008-A | Compound, device and application thereof | 西吉隆医疗股份有限公司 | 2019-07-19 | — | — | CN | disclosed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | disclosed |
| EP-2531221-B1 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS | IC DISCOVERY GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| WO-2019035927-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190029990-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2019-01-31 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-11-13 | — | — | US | disclosed |
| EP-2714677-B1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| EP-3347010-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, LLC (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3344613-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | Dong-A Socio Holdings Co., Ltd. (KR) | 2018-07-11 | — | — | EP | disclosed |
| WO-2018071399-A1 | NANOPARTICLE FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | ABRAXIS BIOSCIENCE, LLC (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | disclosed |
| EP-3309150-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-12-14 | — | — | US | disclosed |
| EP-2630196-B1 | CYANINE DYES AND THEIR CONJUGATES | LI COR INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2673284-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2943473-B1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARM INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170165219-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2017-06-15 | — | — | US | disclosed |
| WO-2017044445-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044443-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
| EP-2855426-B1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2017-01-04 | — | — | EP | disclosed |
| EP-2576585-B1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2880123-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| US-9458128-B2 | Catechol O-methyltransferase activity inhibiting compounds | ORION CORPORATION (FI) | 2016-10-04 | — | — | US | disclosed |
| US-20160263249-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263249-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263249-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2016-09-15 | — | — | US | disclosed |
| EP-3062825-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | Beth Israel Deaconess Medical Center (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9408924-B2 | Bioconjugates of cyanine dyes | LI-COR, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9403859-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9365511-B2 | Biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders | ARENA PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160145281-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-26 | — | — | US | disclosed |
| CN-103748086-B | Pyridine and pyrazines derivatives | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | CN | disclosed |
| US-9273029-B2 | Pyridine-and pyrazine derivatives | MERCK PATENT GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20150367004-A1 | COMPOSITIONS AND METHODS OF DIAGNOSING OCULAR DISEASES | THE REGENT OF THE UNIVERSITY OF CALIFORNIA | 2015-12-24 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9211349-B2 | Molecular probes for multimodality imaging of anionic membrane surfaces | MOLECULAR TARGETING TECHNOLOGIES, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150353488-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2943473-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20150218124-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2015-08-06 | — | — | US | disclosed |
| EP-2880123-A2 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | Roche Diagnostics GmbH (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-20150140682-A1 | IRIDIUM-BASED COMPLEXES FOR ECL | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-05-21 | — | — | US | disclosed |
| WO-2015066290-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066290-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119553-A1 | BIOCONJUGATES OF CYANINE DYES | LI-COR, INC. | 2015-04-30 | — | — | US | disclosed |
| EP-2855426-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | Orion Corporation (FI) | 2015-04-08 | — | — | EP | disclosed |
| CN-103038245-B | Modified c-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8927719-B2 | Cyanine dyes and their conjugates | LI-COR, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8877171-B2 | Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis | MIVENION GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8835637-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| WO-2014110103-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2014092958-A1 | COMPOSITIONS AND METHODS OF DIAGNOSING OCULAR DISEASES | MOLECULAR TARGETING TECHNOLOGIES, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-8754068-B2 | Modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140142097-A1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| CN-103748086-A | Pyridine-and pyrazine derivatives | MERCK PATENT GMBH | 2014-04-23 | — | — | CN | disclosed |
| EP-2411365-B1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-03-19 | — | — | EP | disclosed |
| WO-2014019707-A2 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| EP-2673284-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | Roche Diagnostics GmbH (DE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013184678-A1 | MOLECULAR PROBES FOR MULTIMODALITY IMAGING OF ANIONIC MEMBRANE SURFACES | MOLECULAR TARGETING TECHNOLOGIES, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| EP-2418203-B1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-20130323172-A1 | MOLECULAR PROBES FOR MULTIMODALITY IMAGING OF ANIONIC MEMBRANE SURFACES | MOLECULAR TARGETING TECHNOLOGIES, INC. | 2013-12-05 | — | — | US | disclosed |
| US-20130323719-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2013175053-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2013-11-28 | — | — | WO | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20130274144-A1 | COMPOUNDS, REACTIONS, AND SCREENING METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLIOIS (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274452-A1 | CYANINE DYES AND THEIR CONJUGATES | MIDCAP FINANCIAL TRUST | 2013-10-17 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| EP-2630196-A1 | CYANINE DYES AND THEIR CONJUGATES | LI-COR, INC. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20130172335-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-8450313-B2 | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130095035-A1 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS | MIVENION GMBH (DE) | 2013-04-18 | — | — | US | disclosed |
| EP-2576585-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-103038245-A | Modified c-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL MYERS SQUIBB CO | 2013-04-10 | — | — | CN | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| EP-2531221-A1 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS | Mivenion GmbH (DE) | 2012-12-12 | — | — | EP | disclosed |
| WO-2012161877-A1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8268820-B2 | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120232071-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HUNZIKER DANIEL (CH) | 2012-09-13 | — | — | US | disclosed |
| WO-2012107419-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-16 | — | — | WO | disclosed |
| US-20120142707-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| WO-2012054749-A1 | CYANINE DYES AND THEIR CONJUGATES | LI-COR, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| EP-2411365-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011153315-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-08 | — | — | WO | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| US-8063088-B2 | Imidazolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| CN-101389613-B | Macrocyclic factor viia inhibitors useful as anticoagulants | BRISTOL MYERS SQUIBB CO | 2011-10-12 | — | — | CN | disclosed |
| WO-2011095311-A1 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS | MIVENION GMBH (DE) | 2011-08-11 | — | — | WO | disclosed |
| EP-2352725-A1 | QUINOXALINE-BASED LXR MODULATORS | Wyeth LLC (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2288594-A1 | IMIDAZOLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2282742-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-7851658-B2 | Palladium-catalyzed carbon-carbon bond forming reactions | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010108903-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010054229-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH LLC (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-7713979-B2 | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2173174-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7652019-B2 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| WO-2009150109-A1 | IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| US-7598251-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7592331-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | SMITHKLINE BEECHAM P.L.C. | 2009-07-02 | — | — | US | disclosed |
| US-20090118313-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM P.L.C. | 2009-05-07 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| CN-101389613-A | Macrocyclic factor viia inhibitors useful as anticoagulants | BRISTOL MYERS SQUIBB CO (US) | 2009-03-18 | — | — | CN | disclosed |
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1807072-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7459454-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7452873-B2 | Inhibitors of GSK-3 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452873-B2 | Inhibitors of GSK-3 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| EP-1971582-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7399645-B2 | Constrained cis-diol-borate bioconjugation system | APPLERA CORPORATION (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1606266-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070287825-A1 | Constrained cis-diol-borate bioconjugation system | APPLERA CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1824812-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1807072-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007076431-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007008226-A9 | PALLADIUM-CATALYZED CARBON-CARBON BOND FORMING REACTIONS | HARVARD COLLEGE (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066851-A1 | Palladium-catalyzed carbon-carbon bond forming reactions | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2007-03-22 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| WO-2007015744-A1 | DISUBSTITUTED THIENYL COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015744-A1 | DISUBSTITUTED THIENYL COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007008226-A2 | PALLADIUM-CATALYZED CARBON-CARBON BOND FORMING REACTIONS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006057922-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006049952-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060084651-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033796-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | WYETH | 2006-03-23 | — | — | US | disclosed |
| EP-1615898-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | Novartis AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| US-20050288337-A1 | Novel compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1606266-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-12-21 | — | — | EP | disclosed |
| US-6936610-B2 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-08-30 | — | — | US | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1539696-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | TRIGEN LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
| WO-2004089913-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004084813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004056798-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004014859-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
| US-20030119178-A1 | DNA chip and its preparation | SATO KOZO (JP) | 2003-06-26 | — | — | US | disclosed |
| WO-2002057273-A9 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LTD (GB) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002057273-A1 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| US-6300330-B1 | BLOOD COAGULATION FACTOR X INHIBITORS AS ANTICOAGULANTS | ZENECA LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| US-20010011129-A1 | DNA chip and its preparation | FUJI PHOTO FILM CO., LTD.; | 2001-08-02 | — | — | US | disclosed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | FFAR1 3621/4885KEAP1 1992/4885TRPV1 1016/4885 |
| US-20150353488-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | HRH3, HRH4, HRH1 | FFAR1 246/4885KEAP1 483/4885TRPV1 222/4885 |
| US-20250255991-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | ERAL1, TK2, PYCR1 | FFAR1 309/4885KEAP1 873/4885TRPV1 811/4885 |
| US-20210077385-A1 | WET-PACKED SOFT HYDROGEL OCULAR INSERTS | BRI3BP, BRWD1, HRH2 | FFAR1 1527/4885KEAP1 3259/4885TRPV1 3584/4885 |
| US-20230416280-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | PAH, BCAT2, BCAT1 | FFAR1 644/4885KEAP1 447/4885TRPV1 3873/4885 |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | FFAR1 3133/4885KEAP1 3854/4885TRPV1 2357/4885 |
| US-20050288337-A1 | Novel compounds | ITGB4, ITGA4, ITGB5 | FFAR1 2500/4885KEAP1 2924/4885TRPV1 1853/4885 |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | FFAR1 3156/4885KEAP1 1245/4885TRPV1 494/4885 |
| US-20070066851-A1 | Palladium-catalyzed carbon-carbon bond forming reactions | APEX1, PCNA, DNMT3A | FFAR1 4211/4885KEAP1 567/4885TRPV1 4863/4885 |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | FFAR1 2489/4885KEAP1 623/4885TRPV1 781/4885 |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | FFAR1 817/4885KEAP1 1188/4885TRPV1 3012/4885 |
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | FFAR1 651/4885KEAP1 1179/4885TRPV1 1700/4885 |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | NR1H2, NR1H3, NR1D2 | FFAR1 66/4885KEAP1 1302/4885TRPV1 808/4885 |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | FFAR1 1891/4885KEAP1 1843/4885TRPV1 2632/4885 |
| US-20070287825-A1 | Constrained cis-diol-borate bioconjugation system | TAC3, CCR3, B3GAT3 | FFAR1 472/4885KEAP1 985/4885TRPV1 4046/4885 |
| US-20130095035-A1 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS | MKI67, PCNA, ACP1 | FFAR1 4287/4885KEAP1 3520/4885TRPV1 4021/4885 |
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | PLA2G4A, PLA2G4B, PLA2G1B | FFAR1 219/4885KEAP1 936/4885TRPV1 1182/4885 |
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | STK25, ABL1, STK35 | FFAR1 4657/4885KEAP1 1304/4885TRPV1 1626/4885 |
| US-12612421-B2 | Method for producing 4-borono-L-phenylalanine and intermediate thereof | BCAT2, BCAT1, CLIC4 | FFAR1 696/4885KEAP1 2231/4885TRPV1 3346/4885 |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | FFAR1 2489/4885KEAP1 623/4885TRPV1 781/4885 |
| US-20130172335-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | FFAR1 63/4885KEAP1 970/4885TRPV1 1698/4885 |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, TSLP, IFNG | FFAR1 2262/4885KEAP1 398/4885TRPV1 2302/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | FFAR1 3729/4885KEAP1 995/4885TRPV1 4872/4885 |
| US-20170165219-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | FFAR1 3526/4885KEAP1 432/4885TRPV1 4268/4885 |
| US-11077210-B2 | Near-infrared fluorescent contrast bioimaging agents and methods of use thereof | CD68, MSR1, CD47 | FFAR1 2863/4885KEAP1 2328/4885TRPV1 2299/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | FFAR1 2/4885KEAP1 1466/4885TRPV1 275/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | FFAR1 755/4885KEAP1 1222/4885TRPV1 3248/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | FFAR1 2489/4885KEAP1 623/4885TRPV1 781/4885 |
| US-20090118313-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | PLAT, PLA2G7, LYPLAL1 | FFAR1 454/4885KEAP1 627/4885TRPV1 2277/4885 |
| US-20200352898-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | FFAR1 3526/4885KEAP1 432/4885TRPV1 4268/4885 |
| US-20220387631-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | CD68, MSR1, CD47 | FFAR1 2863/4885KEAP1 2328/4885TRPV1 2299/4885 |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | FFAR1 34/4885KEAP1 898/4885TRPV1 398/4885 |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | FFAR1 2489/4885KEAP1 623/4885TRPV1 781/4885 |
| US-12545641-B2 | Amphoteric fluorescent substance capable of being attached to biomaterials | EPCAM, CD44, MKI67 | FFAR1 3567/4885KEAP1 3349/4885TRPV1 918/4885 |
| US-20120142707-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BET1, BIRC3, CYTH3 | FFAR1 3961/4885KEAP1 3006/4885TRPV1 4761/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | FFAR1 34/4885KEAP1 898/4885TRPV1 398/4885 |
| US-20150140682-A1 | IRIDIUM-BASED COMPLEXES FOR ECL | ALPL, LIG3, SOD3 | FFAR1 4813/4885KEAP1 1166/4885TRPV1 4775/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | FFAR1 817/4885KEAP1 1188/4885TRPV1 3012/4885 |
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | FFAR1 66/4885KEAP1 981/4885TRPV1 1553/4885 |
| US-20120232071-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | FFAR1 63/4885KEAP1 970/4885TRPV1 1698/4885 |
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSDL2, HSD17B1 | FFAR1 264/4885KEAP1 905/4885TRPV1 4175/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | FFAR1 755/4885KEAP1 1222/4885TRPV1 3248/4885 |
| US-20010011129-A1 | DNA chip and its preparation | STUB1, DNMT3A, PCNA | FFAR1 2894/4885KEAP1 3013/4885TRPV1 4841/4885 |
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | FFAR1 32/4885KEAP1 4818/4885TRPV1 4725/4885 |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | FFAR1 2489/4885KEAP1 623/4885TRPV1 781/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | FFAR1 362/4885KEAP1 1680/4885TRPV1 1136/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | FFAR1 3729/4885KEAP1 995/4885TRPV1 4872/4885 |
| US-11945786-B2 | Compounds, devices, and uses thereof | SLC10A1, SLCO1B3, SLC5A1 | FFAR1 3156/4885KEAP1 1245/4885TRPV1 494/4885 |
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | FFAR1 421/4885KEAP1 539/4885TRPV1 4473/4885 |
| US-20250325713-A1 | DISEASE-TARGETED IMAGING AGENTS | FAP, PROKR1, GRPR | FFAR1 335/4885KEAP1 2070/4885TRPV1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.